Amoeba SA

Amoeba SA is a France-based company that develops, manufactures and markets biological products. The Company specializes in disruptive biological solutions for the treatment of Legionella, amoeba and biofilm in water. The Company's offering includes products and services, such as: Cleantech biological solution, a patented technological disruptive product with no impact on the environment; amoebic analyses of waters of wet cooling towers (TAR), hot sanitary waters, industrial waters and waters of swimming pools; as well as Legionella tests of industrial waste water, among others. The Company is engaged in various technical, commercial, industrial and investment partnerships.
  • TickerAMEBA
  • ISINFR0011051598
  • ExchangeEuronext Paris
  • SectorChemicals
  • CountryFrance

Analysts

Jehanne Leroy

Amoeba SA - Proxy Report - 10/10/2018

Le principal objet de la présente assemblée est l'autorisation d'émettre 300 Obligations Convertibles en Actions de 20 000 € de nominal (soit au totale une émission de 6 M€ en nominal) au bénéfice d'une société de droit suisse, Nice & Green.La société indique que cette opération s'inscrit dans s stratégie de renforcement des fonds propres. Si l’on comprend les raisons évoquées par la société, elle n’explique cependant pas pourquoi elle a choisi de faire une émission sans DPS au lieu d’une émission avec DPS à laquelle tous ses actionnaires actuels, confiants en la stratégie de la société, aurai...

Pierre-Antoine Chazal

Amoéba: H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval (

Amoéba: (CORPORATE, Fair Value EUR13 (+192%)) H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the company to continue its activities until the end of August 2019. All eyes remain on the potential US appro...

1 director sold

A director at Amoeba sold 52,256 shares at 6.420EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Pierre-Antoine Chazal

Amoéba: H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval (

Amoéba: (CORPORATE, Fair Value EUR13 (+192%)) H1 2018 bottom line impacted by restructuring expenses - all eyes on potential US approval Amoeba unveiled its H1 2018 results on Friday evening with revenue at EUR62k vs. EUR75k last year. H1 2018 net income was down yoy mainly due to the impact from restructuring expenses as announced by the company earlier this year. The group's cash position stood at EUR6.3m at end-June vs. EUR7.38m at end-April. The current cash position should enable the company to continue its activities until the end of August 2019. All eyes remain on the potential US appro...

1 director sold

A director at Amoeba sold 52,256 shares at 6.420EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Jehanne Leroy

Amoeba SA - Proxy Report - 10/10/2018

Le principal objet de la présente assemblée est l'autorisation d'émettre 300 Obligations Convertibles en Actions de 20 000 € de nominal (soit au totale une émission de 6 M€ en nominal) au bénéfice d'une société de droit suisse, Nice & Green.La société indique que cette opération s'inscrit dans s stratégie de renforcement des fonds propres. Si l’on comprend les raisons évoquées par la société, elle n’explique cependant pas pourquoi elle a choisi de faire une émission sans DPS au lieu d’une émission avec DPS à laquelle tous ses actionnaires actuels, confiants en la stratégie de la société, aurai...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch